Abstracts tagged "drug therapy"

Abstract Number: 1595 • 2012 ACR/ARHP Annual Meeting
Genome-Wide Association Study to High -Throughput Cell-Based Phenotypic Screen Identifies Novel Chemical Inhibitors of CD40 Signaling
Gang Li¹, Dorothee Diogo², Di Wu¹, Jim Spoonamore³, Rheumatoid Arthritis Consortium International (RACI)⁴, Eli Stahl⁵, Nicola Tolliday³ and Robert M. Plenge⁶, ¹Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Broad Institute, Cambridge, MA, ⁴Boston, ⁵Brigham and Women's Hospital, ⁶Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Deriving therapeutic targets from human genetics linked with biological alterations of risk alleles may provide a more successful approach to drug development than traditional…
Abstract Number: 1149 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Etanercept in Patients with Juvenile Idiopathic Arthritis (JIA)
Kirsten Minden¹, Martina Niewerth², Jens Klotsche³, Michael Hammer⁴, Johannes Peter Haas⁵, Gerd Ganser⁶ and Gerd Horneff⁷, ¹Programme Area Epidemiology, German Rheumatism Research Center, a Leibniz Institute, Berlin, Germany, ²Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ³Programme Area Epidemiology, German Rheumatism Research Center, a Leibniz institute, Berlin, Germany, ⁴Klinik fuer Rheumatologie, St. Josef-Stift, Sendenhorst, Germany, ⁵German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ⁶Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ⁷Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany
Background/Purpose: Etanercept (Eta) has been the most frequently used biologic drug in patients with JIA. In Germany, about one in three patients with polyarticular JIA…
Abstract Number: 802 • 2012 ACR/ARHP Annual Meeting
Milnacipran Reduces Brain Activity During Pain in Fibromyalgia
Anson E. Kairys¹, Richard E. Harris², Eric Ichesco², Johnson P. Hampson², Steven Harte², Daniel J. Clauw³ and Tobias Schmidt-Wilcke², ¹Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ²Anesthesiology, University of Michigan, Ann Arbor, MI, ³Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI
Background/Purpose: Fibromyalgia (FM) is a chronic pain condition characterized by widespread musculoskeletal pain and a number of concomitant symptoms such as fatigue, sleep disturbance, cognitive…
Abstract Number: 805 • 2012 ACR/ARHP Annual Meeting
Milnacipran Increases Cortical to Brainstem Connectivity During Pain in Fibromyalgia
Eric Ichesco¹, Tobias Schmidt-Wilcke¹, Anson E. Kairys², Johnson P. Hampson¹, Steven E. Harte¹, Daniel J. Clauw³ and Richard E. Harris¹, ¹Anesthesiology, University of Michigan, Ann Arbor, MI, ²Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ³Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI
Background/Purpose: Fibromyalgia (FM) is a chronic widespread pain disorder characterized by muscle tenderness, fatigue, poor sleep, and mood disturbance. Milnacipran is a dual serotonin-norepinephrine reuptake…
Abstract Number: 642 • 2012 ACR/ARHP Annual Meeting
Effects of Treatment On the Expression of CCL2 and CXCL10 in Systemic Lupus Erythematosus Patients
Paul R. Dominguez-Gutierrez¹, Angela Ceribelli¹, Minoru Satoh², Eric S. Sobel³, Westley H. Reeves⁴ and Edward K.L. Chan¹, ¹Oral Biology, University of Florida, Gainesville, FL, ²Medicine, University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁴Rheumatology & Clinical Imm, University of Florida, Gainesville, FL
Background/Purpose: Several candidate biomarkers for Systemic Lupus Erythematosus (SLE) have been reported including STAT1, ADAR, CCL2, CXCL10, and miR-146a. This study examines the effects of…
Abstract Number: 497 • 2012 ACR/ARHP Annual Meeting
Golimumab Drug Utilization Patterns in Canada – Higher Retention Rate in Golimumab Treated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab
Hayssam Khalil¹ and Amir Tahami², ¹Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ²Janssen Canada Inc., Toronto, ON, Canada
Background/Purpose: Golimumab is a monthly self-injected anti-tumor necrosis factor alpha therapy for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). It…
Abstract Number: L13 • 2012 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial
Arthur Kavanaugh¹, Philip J. Mease², Juan J. Gomez-Reino³, Adebajo Adewale⁴, Jürgen Wollenhaupt⁵, ChiaChi Hu⁶ and Randall Stevens⁶, ¹UCSD School of Medicine, La Jolla, CA, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁴University of Sheffield, Sheffield, United Kingdom, ⁵Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁶Celgene Corporation, Warren, NJ
Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate a network of pro- and anti-inflammatory mediators, including those implicated in the etiopathogenesis of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].